About Rebif® (interferon beta-1a)
Rebif is the only self-injected relapsing MS therapy proven to meet 3 key treatment goals in relapsing MS
This was shown in a large placebo-controlled study of Rebif for relapsing MS.
Slowing disability progression
Reducing relapse rate
Reducing active brain lesions on studied MRI measures*†
The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.
Benefits of Rebif
With Rebif, you get more than an effective treatment and a well-established safety profile. You also get a relapsing MS treatment with product features designed for flexibility and support services that can help you start—and stay—on therapy.
Rebif has a well-established safety profile, with more than 19 years of clinical trial and patient experience.
Important safety information
Rebif will not cure multiple sclerosis (MS) but it has been shown to decrease the number of flare-ups and slow the occurrence of some of the physical disability that is common in people with MS. Rebif can cause serious side effects, so before you start taking Rebif, you should talk with your doctor about the possible benefits of Rebif and its possible side effects to decide if Rebif is right for you.
Please see important safety information below and the Rebif Medication Guide and Prescribing Information in the top of this website, and speak with your health care provider for more information.
Rebif is the only self-injected relapsing MS therapy proven to work better than another in a class 1 clinical trial‡.
With Rebif, you get more than an effective treatment—you get one–on–one nursing and financial support through MS LifeLines®.
What is interferon beta-1a?
Rebif is an interferon therapy. Interferons belong to a family of proteins that naturally occur in the body. Rebif contains interferon beta-1a. The exact way Rebif works is not known.
Although there is no cure for relapsing MS, Rebif has been proven to slow the progression of disability, which is the permanent worsening of your neurologic examination over time.
*Refers to new lesion burden or area as defined in the AAN and MS Council guidelines.
†New or enlarging lesions detected with PD/T2-weighted MRI.
‡According to the American Academy of Neurology, data from class I studies are collected under the highest scientific standards and are thought to be the most valid.